首页 / 产品 / 抗体 / 一抗

Rabbit Polyclonal KMT6 Antibody

  • 中文名: KMT6抗体
  • 别    名: WVS; ENX1; KMT6; WVS2; ENX-1; EZH2b; KMT6A; EZH2
货号: IPDX22880
Price: ¥1180
数量:
大包装询价

验证与应用

应用及物种
WB 1/500-1/1000 Human,Mouse,Rat
IF 咨询技术 Human,Mouse,Rat
IHC 1/50-1/100 Human,Mouse,Rat
ICC 1/50-1/200 Human,Mouse,Rat
FCM 1/50-1/100 Human,Mouse,Rat
Elisa 咨询技术 Human,Mouse,Rat

产品详情

AliasesWVS; ENX1; KMT6; WVS2; ENX-1; EZH2b; KMT6A; EZH2
Entrez GeneID2146
WB Predicted band sizeCalculated MW: 85 kDa; Observed MW: 98 kDa
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman,Mouse,Rat
ImmunogenA synthesized peptide derived from human KMT6 / EZH2
FormulationPurified antibody in PBS with 0.05% sodium azide.

+ +

参考文献

以下是关于KMT6(EZH2)抗体的3篇参考文献示例(注:以下为模拟示例,非真实文献):

---

1. **文献名称**:*"Development of a High-Affinity Monoclonal Antibody for EZH2 with Applications in Cancer Diagnostics"*

**作者**:Chen L, et al.

**摘要**:研究团队开发了一种针对EZH2的高特异性单克隆抗体,验证其在免疫组织化学(IHC)和流式细胞术中的有效性,并证明其在乳腺癌和淋巴瘤临床样本中检测EZH2过表达的潜力。

2. **文献名称**:*"EZH2 Antibody-Based Detection of H3K27me3 Modifications in Glioblastoma Progression"*

**作者**:Wang X, et al.

**摘要**:通过新型EZH2抗体结合ChIP-seq技术,揭示了胶质母细胞瘤中H3K27me3修饰的动态变化,发现其与肿瘤侵袭性和化疗耐药性的相关性。

3. **文献名称**:*"A Novel Rabbit Polyclonal Antibody Against EZH2 for Epigenetic Mechanism Studies"*

**作者**:Kim S, et al.

**摘要**:报道了一种兔源多克隆抗体的制备,该抗体在Western blot和免疫荧光中表现出高灵敏度,用于研究EZH2在干细胞分化中的表观遗传调控作用。

---

如需真实文献,建议通过PubMed或Google Scholar搜索关键词“EZH2 antibody”、“KMT6A/B antibody”或结合具体应用场景(如“cancer”、“H3K27me3”、“ChIP-seq”)。近年研究多集中于抗体在疾病诊断或靶向治疗中的开发。

背景信息

KMT6. also known as EZH2 (Enhancer of Zeste Homolog 2), is a histone methyltransferase and a core component of the Polycomb Repressive Complex 2 (PRC2). It catalyzes the trimethylation of histone H3 at lysine 27 (H3K27me3), a key epigenetic modification associated with transcriptional repression. This enzyme plays a critical role in regulating gene expression patterns during development, stem cell differentiation, and cell cycle progression. Dysregulation of KMT6/EZH2 is implicated in various cancers, where its overexpression often correlates with tumor aggressiveness, metastasis, and poor prognosis. In malignancies such as lymphoma, breast cancer, and prostate cancer, aberrant H3K27me3 levels drive silencing of tumor suppressor genes. KMT6 antibodies are essential tools for studying these mechanisms, enabling detection of EZH2 expression and H3K27me3 marks in cells and tissues via techniques like Western blot, immunohistochemistry, and ChIP-seq. Additionally, they aid in exploring therapeutic strategies targeting PRC2 activity, with EZH2 inhibitors currently in clinical trials for cancers with KMT6 pathway alterations. Research using KMT6 antibodies continues to uncover its dual oncogenic/tumor-suppressive roles, depending on cellular context, highlighting its complexity in disease biology and therapeutic targeting.

客户数据及评论

折叠内容

大包装询价

×